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Abstract The inherited 5-oxoprolinuria is primarily sug-
gestive of genetic defects in two enzymes belonging to the
gamma-glutamyl cycle in the glutathione (GSH) metabo-
lism: the glutathione synthetase (GSS) and the 5-oxoproli-
nase (OPLAH). The GSS deficiency is the best characterized
of the inborn errors of GSHmetabolism,whereas theOPLAH
deficiency is questioned whether it is a disorder or just a
biochemical condition with no adverse clinical effects.
Recently, the first human OPLAH mutation (p.H870Pfs)
was reported in homozygosis in two siblings who suffered
from 5-oxoprolinuria with a benign clinical course. We
report two unrelated patients who manifested massive
excretion of 5-oxoproline in urine. In both probands,
the blood GSH levels were normal and no mutations
were found in the GSS gene. The mutational screening of
the OPLAH gene, which included the codified sequences,
the intronic flanking sequences, the promoter sequence, and
a genetic analysis in order to detect large deletions and/or
duplications, showed that each patient only harbors one
missense mutation in heterozygosis. The in silico analyses
revealed that each one of these OPLAH mutations, p.S323R
and p.V1089I, could alter the proper function of this
homodimeric enzyme. In addition, clinical symptoms
manifest in these two probands were not related to GSH
cycle defects and, therefore, this study provides further
evidence that oxoprolinuria may present as epiphenomenon
in several pathological conditions and confound the final
diagnosis.
Introduction
There are several metabolic disturbances that are ques-
tioned if they only are a casual finding during biochemical
screening of patients or have a direct clinical involvement.
One of them is the 5-oxoprolinuria (pyroglutamic aciduria)
whose etiology remains elusive in some circumstances.
Several diseases and environmental conditions (special
diets, drug metabolism and drug treatment, prematurity,
malnutrition, some inborn errors of metabolism) have been
associated with oxoprolinuria (Schwahn et al. 2005; Ruijter
et al. 2006; Ristoff and Larsson 2007), although the
hereditary 5-oxoprolinuria is primarily suggestive of
genetic defects in two enzymes belonging to the gamma-
glutamyl cycle in the glutathione (GSH) metabolism: the
glutathione synthetase (GSS; EC 6.3.2.3) and the
5-oxoprolinase (OPLAH; EC 3.5.2.9).
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The glutathione synthetase deficiency (MIM 266130) is
the best characterized and the most common of the inborn
errors of GSH metabolism (Njalsson 2005; Ristoff and
Larsson 2007). It presents with a wide spectrum of clinical
signs. The most frequent hallmarks are 5-oxoprolinuria,
metabolic acidosis and hemolytic anemia, and in severely
affected patients, the central nervous system is affected.
This deficiency is caused by mutations in the GSS gene and
more than 30 mutations have been described which are
transmitted in an autosomal recessive fashion (Al-Jishi
et al. 1999; Dahl et al. 1997; Njalsson et al. 2003; Shi et al.
1996). Heterozygous carriers of GSS mutations are healthy
and show an enzyme activity of 55% of the normal mean
and normal levels of GSH (Njalsson et al. 2005). However,
the 5-oxoprolinase deficiency (MIM 260005) is questioned
whether it is a disorder or just a biochemical condition with
no adverse clinical effects. To date, nine probands with 5-
oxoprolinuria and a low activity of 5-oxoprolinase have
been described worldwide (Almaghlouth et al. 2011;
Bernier et al. 1996; Cohen et al. 1997; Henderson et al.
1993; Larsson et al. 1981; Mayatepek et al. 1995; Roesel
et al. 1981). These patients lack a consistent clinical picture
except for the 5-oxoprolinuria. Symptoms reported in
individual patients include renal stone formation, mental
retardation, neonatal hypoglycaemia, microcytic anemia,
and microcephaly. The 5-oxoprolinase is encoded by the
OPLAH gene, and mutations in this gene are expected to
lead to a 5-oxoprolinase deficiency transmitted in an
autosomal recessive manner. Recently, the first human
OPLAH mutation (p.H870Pfs) was reported, which predicts
a truncated protein. This change was identified in homo-
zygosis in two siblings with a persistent increased 5-
oxoproline excretion and with a benign clinical course
(Almaghlouth et al. 2011).
Here we report two new unrelated patients who
manifested a massive excretion of 5-oxoproline in urine.
After an exhaustive genetic analysis, in each patient, only
one heterozygous missense mutation was identified in the
OPLAH gene, suggesting that only one mutation could alter
the normal activity of this homodimeric enzyme. Moreover,
clinical features in these two probands were not related
supporting the 5-oxoprolinase deficiency is a benign
biochemical condition.
Materials and Methods
Patients This study protocol was approved by the ethics
committee of the Hospital Sant Joan de Déu. Written
informed consent was obtained from parents of the patients.
Case 1 The patient is a 1.5-month-old girl (ID no. 943,
family AR-141; Fig. 1a), the first child of healthy non-
consanguineous parents from Indian origin, with an unevent-
ful pregnancy and delivery. She was admitted in our hospital
due to repeated episodes of choking (respiratory difficulties
and perioral cyanosis shortly after breast feeding) and
generalized tonic-clonic seizures. First baseline tests revealed
hypocalcemia (1.4 mmol/L; control values: 2.1–2.7),
increased phosphate values (2.8 mmol/L: control values
1.4–2.2), 25 hydroxyvitamin D deficiency (5.5 ng/mL:
control values 12–62), increased PTH values (15.6 pmol/L:
control values 0.5–5.5) normocytic normochromic anemia
(hemoglobin: 8.5 g/dL: control values 9.0–13.0) with low
plasma cobalamin (139 pmol/L: control values >198),
normal plasma total homocysteine values (3.8 mmol/L:
control values < 7.5), and metabolic acidosis. EEG and
brain ultrasound were normal. General and neurological
examinations were normal between episodes. The patient
was treated with oral vitamin D supplementation and
intramuscular vitamin B12 due to a suspicion of deficiency
related to maternal vegetarian diet. The outcome was
excellent with no other seizure recurrence, normalization of
all altered biochemical parameters, and normal developmen-
tal delay at 1 year of age. Urine organic acids were analyzed
three times, disclosing increased pyroglutamic acid excretion
twice during decompensation (7,828 mmol/mol creatinine
and 3,255 mmol/mol creatinine) which led us to the
suspicion of pyroglutamic aciduria. These values were
completely normalized at 1 year of age (9 mmol/mol
creatinine; reference values <10). No causes of secondary
increased excretion of pyroglutamic acid were detected
including special diets, drugs (vigabatrin paracetamol and
antibiotics), inborn errors of metabolism (urea cycle defects,
cystinosis, tyrosinemia, and homocystinuria) and low glycine
values secondary to malnutrition. Blood glutathione levels
were normal (3.2 mmol/L; reference values: 1.5–3.1).
Case 2 An 8-year-old boy (ID no. 1037, family AR-152;
Fig. 1a) diagnosed of Duchenne muscular dystrophy
(DMD; MIM 310200) harboring a deletion that encom-
passes exons 46 to 51 at the dystrophin gene. Familiar
antecedents were uneventful. Clinical presentation at the
moment of exploration was classical, with muscular
involvement and mental disability. No other symptoms or
signs were present. Blood count (no anemia) and other
routine laboratory parameters were normal besides
increased serum creatine kinase activity. Urine organic
acids were collected to study metabolomic profile by gas
chromatography mass spectrometry, and we encountered a
serendipitous finding of increased excretion of pyrogluta-
mic acid (13,208 mmol/mol creatinine: reference values:
<10). This huge excretion was further confirmed in a
second urine sample (7,931 mmol/mol creatinine). In that
moment, patient was under corticoid therapy (prednisone,
20 mg/day). No causes of secondary increased excretion of
pyroglutamic acid were detected. Blood GSH values in
were normal (2.45 mmol/L, reference values: 1.5–3.1).
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Biochemical analyses Organic acids in urine were
analyzed by gas chromatography/mass spectrometry (GC-
MS) (Agilent Technologies Inc., Santa Clara, CA, USA)
after extraction of the urine sample with ethylacetate and
diethyleter and derivatization with N,N-bis(trimethylsilyl)
trifluoroacetamide. The concentration of pyroglutamic acid
was quantified by comparing the signal of m/z 156 obtained
with standard solutions of the pure compound, using
undecanoate as internal standard.
Genetic analyses A search for mutations was performed
by Sanger sequencing of the PCR products of exons and
their intronic flanking sequences in the GSS gene
(NM_000178) as well as in the OPLAH gene
(NM_017570.3) in an ABI Prism 3130xl autoanalyzer
(Applied Biosystems, Foster City, CA, USA). The promoter
sequence was also analyzed in the OPLAH gene.
With the aim to discard the possible existence of large
deletions or insertions, we amplified all the codified exons
and introns of the OPLAH gene (9,007 bp) in the two
probands, the available relatives (ID no. 943’s parents), and
three control subjects. The PCR was performed using
Long PCR Enzyme Mix (Mbi Fermentas, Glen. Burnie,
MD, USA) and the following primers: forward
50-GTGGGTCTCTCCCTCAGGAACC-30, and reverse
50-CTGCAGCTCCGAGTCTCAGTGTC-30. The amplified
product was resolved by 0.8 % agarose electrophoresis. To
improve the resolution of this study, the PCR products were
separately digested with two enzymes, BamHI and XhoI,
which cut four or three times respectively. The digested
fragments were under 5,500 bp and they were resolved by
0.8 % agarose electrophoresis.
ID no. 1037 CONTROL
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Fig. 1 Genetic findings. (a) Available DNAs from probands and their
relatives. (b) Electrophoregrams show the identified mutations in
proband ID no. 943 (c. 969C>A, p.S323R) and in proband ID no.
1037 (c.3265G>A, p.V1089I) in the OPLAH gene, together with the
corresponding controls’ electrophoregrams. (c) Electrophoresis gel
shows the obtained band of 9,0-kb which corresponds to the
amplification of the OPLAH gene. No differences were found in any
of the analyzed samples ruling out large deletions or duplications (1st
and 8th lanes: MWM, Molecular Weight Marker, 1-kb plus DNA
ladder; 2nd lane: –Ctrl, PCR negative control; 3rd to 6th lanes:
analyzed DNAs, 942, 943, and 944 from family AR-141, and 1037
from family AR-152; 7th lane: +Ctrl, DNA from a healthy subject).
(d) Alignment of sequences of the OPLAH protein from human,
bovin, mouse, rat, and yeast showing that both mutated residues are
conserved amino acids. Identical amino acids in all of these sequences
are indicated with an asterisk (*). The closest ATP-binding site to the
p.S323R change is shown, which consists of the sequence DMGGT
(from residue 324 to 328 in yeast)
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Each identified change was also analyzed in more than 250
chromosomes from healthy individuals using DHPLC (Dena-
turing High Performance Liquid Chromatography; Trans-
genomic WAVE, Crewe, UK). We also investigated in silico
the biological relevance of the mutated residues. Conservation
of residues was analyzed by alignment of related sequences
using the program BLAST (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) (Altschul et al. 1990). Sequence-based predictions
of the phenotypic consequences of mutation were assessed
using the SIFT (http://sift.jcvi.org/) and the PolyPhen (http://
genetics.bwh.harvard.edu/pph/) softwares.
Results
No mutations were detected in the GSS gene in any of the
two probands. In patient ID no. 943, a novel change was
detected in the OPLAH gene: c.969C>A (Fig. 1b), which is
predicted to generate the novel p.S323R amino acid
change. We also analyzed her parents, and the mother was
a heterozygous carrier of the p.S323R change whereas the
father did not harbor it. In the three available samples, we
discarded the existence of large deletions or duplications in
the OPLAH gene (Fig. 1c). The p.S323R was not detected
in 128 control subjects. The residue S323 is an evolutionary
conserved amino acid, invariant across more than 100
different species (Fig. 1D). Both SIFT and PolyPhen
algorithms predicted that the p.S323R change would be
probably damaging.
Patient ID no. 1037 was carrier of the OPLAH
c.3265G>A change (Fig. 1b), which is predicted to
produce the p.V1089I amino acid change. Large deletions
and/or duplications of the OPLAH gene were ruled out in
this patient (Fig. 1c). A search for the p.V1089I change was
performed in 154 healthy individuals and this was observed
as a heterozygous change in three individuals. In fact, this
change is annotated as SNP rs185836803 in dbSNP
database (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?
rs¼185836803), although information about heterozygosity
is not available. The residue V1089 is a relatively
conserved amino acid (Fig. 1d). Results obtained from the
in silico analysis were controversial: the SIFT software
predicted that p.V1089I could be tolerated and the Poly-
Phen algorithm that this would be damaging.
Discussion
Several inborn errors of GSH metabolism are known,
glutathione synthetase deficiency being the first cause of
GSH cycle diseases (Shi et al. 1996). GSH takes part in
multiple fundamental processes apart of being one of the
most important antioxidants in the eukaryotic organism.
Deficiency of glutathione synthetase could affect the central
nervous system and other tissues and may cause neurologi-
cal involvement and anemia, among other signs. Thus, the
massive excretion of 5-oxoproline in our patients could be
attributed to mutations in the GSS gene, although GSH
values in blood were within normal limits and no mutations
were identified in the GSS gene in any of our two probands,
ruling out this diagnosis.
The deficiency of 5-oxoprolinase has been associated
with a wide spectrum of clinical symptoms (Ristoff and
Larsson 2007). To date only one homozygous mutation
has been described in two siblings who show a benign
clinical course but with a persistent increased excretion of
5-oxoproline (Almaghlouth et al. 2011). The proband ID
no. 943 presented with an increased urinary excretion of
5-oxoproline at the beginning of the clinical picture, which
spontaneously normalized at 1 year of age, together with a
complete recovery of her clinical picture. In this case, we
cannot rule out that low vitamin D and cobalamin levels
could reflect a malnutrition status that could contribute to
the pyroglutamic aciduria. Nevertheless, the presence of the
reported mutation was probably necessary for triggering
the pyroglutamic aciduria, since no hyperhomocysteinemia
was revealed in this patient and plasma glycine values were
always normal. The proband ID no. 1037 was a patient with
a classical Duchenne clinical presentation, with no other
signs that could be attributed to oxoprolinuria. In each of
them, only one missense change in heterozygosis was
identified in the OPLAH gene after analyzing the codified
exons, their intronic flanking regions, and the promoter
sequence, and discarding large deletions/insertions. Thus,
another mutation in the OPLAH gene is improbable except
located in a deep intronic region. Splicing mutations
account for around 10 % of all reported mutations and
deep intronic mutations represent less than 1 % of known
splicing mutations (Cooper et al. 2010). All these data
together suggest that these two probands seem to be carriers
of only one defect in the OPLAH gene.
Both mutations were detected in healthy subjects:
p.V1089I in three controls and the p.S323R in the proband
ID no. 943’s mother. The clinical course of the two patients
with known mutations in the OPLAH gene is largely benign
(Almaghlouth et al. 2011), as confirmed in our first case.
Concerning the second case, DMD is an X-linked neuro-
muscular disorder due to mutations in the gene encoding
dystrophin, and therefore has a well-defined etiology.
Patients diagnosed of DMD and also with oxoprolinuria
have not been reported. We tested pyroglutamic acid
excretion in urine in five further patients with DMD, but
disclosed normal results (data not shown). Therefore,
persistent oxoprolinuria in the proband ID no. 1037 does
not seem to be related to the DMD. Two female siblings
were reported with a severe neurological picture, but only
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one of them manifested oxoprolinuria (Cohen et al. 1997).
In that case, authors concluded that both siblings suffered
from an unknown hereditary disease, unrelated to the
5-oxoprolinase deficiency observed in one of them. In the
aggregate, our study supports the proposition that defi-
ciency of 5-oxoprolinase is a benign condition. For this
reason, mutations in the OPLAH gene could remain
undiscovered since they probably would not lead to
relevant clinical symptoms but may cause biochemical
alterations that confound the final diagnosis.
This study reveals that heterozygous missense mutations
in the OPLAH gene could cause oxoprolinuria. The in silico
analyses show that both mutations could be pathological.
For both changes, the sequence alignment revealed that the
affected residues are conserved throughout evolution, being
identical in mammals and yeast (Fig. 1d). At least one of
the algorithms used to predict the possible pathogenicity
revealed that each one of these mutations could
be damaging. Little is known about the functionality of
the human 5-oxoprolinase. In Saccharomyces cerevisiae,
the OXP1/YKL215c encodes for an ATP-dependent
5-oxoprolinase (Kumar and Bachhawat 2010). This enzyme
functions as a dimer and contains two distinct domains.
The first domain, from residue 1 to 736, is the actin-like
ATPase motif which contains three essential ATP-binding
sites. The function of the second motif, from residue 745 to
1286, remains confused. Thus, the OPLAH p.S323R would
be located in the first domain extremely close to one of the
ATP-binding sites (Fig. 1d), suggesting that this change in
the human 5-oxoprolinase is probably affecting the proper
activity of the enzyme. Regarding the OPLAH p.V1089I,
this change would be placed in the second domain whose
function is still unknown. This change has been recently
annotated as SNP rs185836803. Other SNPs have been
annotated in the public databases associated with diseases.
Thus, the overwhelming majority of cases of familial
amyloid polyneuropathy (FAP; MIM 105210) result from
the p.V30M substitution in the TTR gene, which is referred
to as SNP rs28933979 (Benson 2001). The fact is that the
OPLAH p.V1089I is the only detected mutation in our
patient and he suffers from a persistent oxoprolinuria.
Unfortunately, we could not measure oxoprolinase
activity since patients did not collaborate with this study
and at present are not controlled in the hospital. How-
ever, the homodimeric structure of the enzyme could make
possible a dominant negative effect of the mutations,
although these are rare in metabolic diseases.
However, some forms of hypophosphatasia (MIM 146300,
241500, 241510) and also of cortisone reductase deficiency
(MIM 604931) can be transmitted in a dominant manner
and in these cases the mutations can exhibit a dominant-
negative effect by inhibiting the enzymatic activity of the
heterodimer (Lawson et al. 2011; Lia-Baldini et al. 2001).
These dominant-negative mutations are in the active site or
in an area which probably affects the formation of
functional dimers. A similar process could occur in
heterozygous patients of 5-oxoprolinase deficiency. In some
particular conditions, interactions between both identical
molecules would not be properly made and would trigger a
massive excretion of 5-oxoproline in urine. This anomalous
biochemical condition would be normalized when the
stressing conditions disappear, as in our proband ID no.
943. In other cases, the oxoprolinuria could persist, as in
our proband ID no. 1037. Further studies are needed to
clarify the possible mechanism causing this biochemical
alteration in heterozygous individuals for OPLAH muta-
tions. Independently, mutational analysis of the OPLAH
gene may be advisable to elucidate causes of unknown
massive pyroglutamic aciduria in order to understand better
this biochemical alteration that may confound the final
diagnosis.
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A Concise One-Sentence Take-Home Message
Oxoprolinuria, due to heterozygous mutations in the 5-
oxoprolinase gene, may present as epiphenomenon in
several pathological conditions and confound the final
diagnosis.
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